Treatment of persistent and recurrent acromegaly

被引:19
作者
Del Porto, Lana A. [1 ]
Liubinas, Simon V. [1 ]
Kaye, Andrew H. [1 ,2 ]
机构
[1] Royal Melbourne Hosp, Dept Neurosurg, Parkville, Vic 3050, Australia
[2] Univ Melbourne, Dept Surg, Parkville, Vic 3052, Australia
关键词
Acromegaly; Persistent; Recurrent; Radiotherapy; Radiosurgery; Somatostatin analogues; Transsphenoidal; GAMMA-KNIFE RADIOSURGERY; GROWTH-FACTOR-I; MESSENGER-RIBONUCLEIC-ACID; TERM-FOLLOW-UP; TRANSSPHENOIDAL SURGERY; STEREOTACTIC RADIOSURGERY; SOMATOSTATIN ANALOGS; PITUITARY-ADENOMAS; HORMONE LEVELS; SLEEP-APNEA;
D O I
10.1016/j.jocn.2010.10.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Acromegaly is a chronic insidious disease characterised by growth hormone (GH) hypersecretion, typically from a pituitary adenoma. Effective treatment of acromegaly is vital because it is associated with a mortality rate more than twice that of the general population, an increased prevalence of colonic malignancy and many significant co-morbidities. Transsphenoidal adenoma resection is still the best first-line treatment for acromegaly but persistence (43%) or recurrence (2% to 3%) of GH hypersecretion after surgery remains a problem. Treatment options for acromegaly after failed initial therapy or recurrence include further surgery, radiotherapy, radiosurgery or medical therapies, including somatostatin analogues, dopamine agonists and growth hormone receptor antagonists. There has been a progressive lowering of the accepted GH level defining cure in acromegaly. This article reviews the efficacy and safety of the various treatment options for persistent or recurrent acromegaly and the changing definition of cure. Crown Copyright (C) 2010 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:181 / 190
页数:10
相关论文
共 96 条
  • [1] Cabergoline in the treatment of acromegaly: A study in 64 patients
    Abs, R
    Verhelst, J
    Maiter, D
    Van Acker, K
    Nobels, F
    Coolens, JL
    Mahler, C
    Beckers, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (02) : 374 - 378
  • [2] Ahmed S, 1999, CLIN ENDOCRINOL, V50, P561
  • [3] EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGION
    ALEXANDER, L
    APPLETON, D
    HALL, R
    ROSS, WM
    WILKINSON, R
    [J]. CLINICAL ENDOCRINOLOGY, 1980, 12 (01) : 71 - 79
  • [4] Gamma-knife radiosurgery in acromegaly: A 4-year follow-up study
    Attanasio, R
    Epaminonda, P
    Motti, E
    Giugni, E
    Ventrella, L
    Cozzi, R
    Farabola, M
    Loli, P
    Beck-Peccoz, P
    Arosio, M
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (07) : 3105 - 3112
  • [5] Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly
    Barkan, AL
    Halasz, I
    Dornfeld, KJ
    Jaffe, CA
    Friberg, RD
    Chandler, WF
    Sandler, HM
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (10) : 3187 - 3191
  • [6] Hormonal and metabolic effects of radiotherapy in acromegaly: Long-term results in 128 patients followed in a single center
    Barrande, G
    Pittino-Lungo, M
    Coste, J
    Ponvert, D
    Bertagna, X
    Luton, JP
    Bertherat, J
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) : 3779 - 3785
  • [7] BATES AS, 1993, Q J MED, V86, P293
  • [8] ACROMEGALY
    BAUMANN, G
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1987, 16 (03) : 685 - 703
  • [9] Ben-Shlomo A, 2007, IDRUGS, V10, P885
  • [10] Predictors and rates of treatment-resistant tumor growth in acromegaly
    Besser, GM
    Burman, P
    Daly, AF
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 153 (02) : 187 - 193